CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Goldenberries have long been a niche curiosity, tucked into specialty produce aisles and health food shops while tomatoes and ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments ahead of Christmas, on December 23, ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its ...

Scientists are using CRISPR to fast-track the domestication of a wild fruit. For roughly 10,000 years, farming communities ...

Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and ...

The global prime editing and CRISPR market size was US$ 3,194.2 million in 2021. The global prime editing and CRISPR market is forecast to grow to US$ 17,618.4 million by 2030 by registering a ...

Across sectors, tech majors worldwide blurred the line between experimental and practical, pushing the world into a new phase ...

A child who received the world's first personalized CRISPR therapy is now taking his first steps after months in hospital ...